Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Interferon beta type 1a Clear all

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BIIB017 (peginterferon beta-1a), Interferon beta type 1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia

Conditions: Multiple Sclerosis
Interventions: mycophenolate mofetil (Cellcept), human interferon beta 1a (Rebif); Drug
Lead sponsor: Aaron Boster; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Sclerosis
Interventions: Interferon beta 1a, oral doxycycline; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b; Drug
Lead sponsor: Teva Neuroscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Swartz Creek, Michigan • Columbus, Ohio • Carnegie, Pennsylvania

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
Interventions: interferon beta 1a, methotrexate, methylprednisolone; Drug
Lead sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Cerebrovascular Accident
Interventions: Interferon beta-1a; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome
Interventions: interferon beta 1a 30 ug IM once weekly; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 20
States / cities: Derby, Connecticut • Tampa, Florida • Atlanta, Georgia + 16 more

Conditions: Multiple Sclerosis
Interventions: Rebif®; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: Up to 18 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Multiple Sclerosis, Low Bone Density
Interventions: Copaxone, Interferon-beta 1a, Interferon-beta 1b; Drug
Lead sponsor: Nancy Hammond, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Kansas City, Kansas

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: RNS60 125 ml, RNS60 250 ml, Interferon beta 1a; Drug
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 85
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a, Daclizumab High Yield Process Placebo; Biological · Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 46
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 8
States / cities: Los Angeles, California • Walnut Creek, California • Shreveport, Louisiana + 5 more

Conditions: Multiple Sclerosis
Interventions: Avonex (Interferon beta 1a), Riluzole, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Combination Therapy Using Cellcept and Rebif in RRMS

Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Study of Evobrutinib in Participants With RMS

Therapy Optimization in Multiple Sclerosis (MS)

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

Safety Study of Interferon Beta 1a to for Acute Stroke

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis